Abstract
A new luminescent, cationic, heteroleptic, four-coordinate Cu(I)–N-heterocyclic carbene complex [Cu(Br-Pyim)(POP)](PF6) is successfully prepared and characterized, where Br-Pyim and POP are 1-(6-bromopyridin-2-yl)imidazole-3-benzyl-2-ylidene and bis[2-(diphenylphosphino)phenyl]ether, respectively. Its detailed structure is determined by single-crystal X-ray analysis. It exists as a crystalline powder at room temperature and exhibits bright yellow-green emission. The use of the Cu(I)–N-heterocyclic carbene complex as a catalyst for amination reactions is also investigated and is found to be very efficient for the amination of 2-N-heteroaryl chlorides with pyrazoles, giving the desired substituted 1-(2-N-heteroaryl)-1H-pyrazoles in good yields.
Keywords
Introduction
N-Arylpyrazoles are important intermediates used in the synthesis of many agrochemicals, pharmaceuticals, and functional materials.1,2 The N-arylpyrazole structural unit can be obtained by several synthetic methods, among which transition-metal-catalyzed amination of aryl halides is one of the most direct and powerful.3–5 In contrast to expensive catalysts such as palladium and rhodium complexes, low-cost copper catalysts are attracting considerable attention due to their potential use in industrial and practical applications.6–9 Many copper/ligand systems have been reported, most of which utilize CuI as the catalyst and other Cu sources (e.g. Cu2O, CuCl). However, the copper/ligand catalytic processes have not been well-determined; in particular, the structures of the Cu(I) pre-catalysts are rarely investigated.8,9
It is well-known that N-heterocyclic carbenes (NHCs) have strong σ-donating and modest π-accepting abilities, which make them widely used as ligands in catalysis and materials science.10–13 Recently, Thompson’s group reported luminescent Cu(I)−NHC complexes, and these complexes exhibited moderate-to-high emission efficiency.14,15 We have also reported several cationic, heteroleptic, four-coordinate Cu(I)−NHC complexes with high emission efficiency and tunable emission wavelengths by modifying the structure of NHC ligands.16,17 In view of these findings and our continuing interest in the synthesis of NHC complexes as well as their application in coupling reactions,18,19 we were interested to investigate whether the obtained Cu(I)–NHC complexes were active for aminations. Thus, we prepared a new photoluminescence Cu(I)–NHC complex and examined its catalytic activity in the amination of pyrazoles.
Results and discussion
Synthesis and structure
The new four-coordinate Cu(I)–NHC complex

Synthesis of four-coordinate Cu(I)–NHC complex

X-ray crystal structure of
Absorption and emission
In CH2Cl2 solution, complex

Absorption and photoluminescence (PL) spectra of
Amination
1-(2-N-Heteroaryl)-1H-pyrazole derivatives as N,N ligands have found widespread applications in the fields of supramolecular chemistry and crystal engineering. Coupling reactions of N-heteroaryl halides have become one of the most valuable synthetic processes for N-heterocyclic compounds.21,22 For example, 2-chloro pyridines and 2-chloropyrimidines are important coupling partners in these reactions.23–25 However, the amination of 2-N-heteroaryl halides with pyrazoles has been relatively less reported.26,27 So, we have investigated the catalytic activity of complex
Initially, the use of complex
Optimization of the reaction conditions for the amination of 2-chloro-5-methylpyridine with 1H-pyrazole. a
THF: tetrahydrofuran; DMF: dimethylformamide; DMSO: dimethyl sulfoxide.
Reaction conditions: 2-chloro-5-methylpyridine (1.0 mmol), 1H-pyrazole (1.1 mmol), base (2.0 mmol), solvent (3 mL), 110 °C, 12 h.
Isolated yield.
Compared with 1H-pyrazole, 3,5-dimethyl-1H-pyrazole showed no deleterious effect on these reactions. Under the optimized reaction conditions, the amination of 3,5-dimethyl-1H-pyrazole with 2-chloro-5-methylpyridine gave product
Aminations of 2-N-heteroaryl chlorides with pyrazoles catalyzed by
Reaction conditions: 2-N-heteroaryl chloride (1.0 mmol), pyrazole (1.1 mmol),
Conclusion
A new photoluminescent four-coordinate Cu–NHC complex has been synthesized and characterized. The complex demonstrates efficient TADF in the solid state at room temperature. In addition, we have developed an efficient method for the amination of N-heteroaryl chlorides with pyrazoles catalyzed by this Cu–NHC complex. This protocol provides an efficient access to a variety of substituted 1-(2-N-heteroaryl) -1H- pyrazoles.
Experimental
Materials and equipment
Solvents were dried and freshly distilled prior to use. All other chemicals were commercially available, expect for 1-(6-bromopyridin-2-yl)-3-benzylimidazolium hexafluorophosphate (Br-HPyimPF6), which was prepared according to the published procedure.16,17 Elemental analyses were determined with a Carlo Erba 1160 Elemental Analyzer. Mass spectra were measured on a LC-MSD-Trap-XCT instrument. 1H, 31P, and 13C NMR spectra were recorded on a Bruker DPX-400 spectrometer (400, 162, and 100 MHz, respectively) with tetramethylsilane (TMS) as an internal standard. The absorption and PL spectra were recorded on a Hitachi U-3010 UV-Vis spectrophotometer and a Hitachi F-4500 fluorescence spectrophotometer.
Synthesis of [Cu(Br-Pyim)(POP)](PF6) 1
Under an N2 atmosphere, Br-HPyimPF6 (1 mmol), copper powder (1.2 mmol), and bis[2-(diphenylphosphino)phenyl]ether (POP, 1 mmol) were stirred in CH3CN (10 mL) at 70 C overnight. After cooling, the resulting mixture was filtered, and then the filtrate was collected and evaporated under vacuum. The residue was dissolved in dichloromethane/ethanol, and the product was obtained as yellow crystals by slow evaporation of the solvent. Yield: 63%. 1H NMR (400 MHz, CD3CN): δ 7.76–7.85 (m, 2H), 7.61–7.68 (m, 1H), 7.34–7.49 (m, 16H), 7.09–7.15 (m, 6H), 7.00–7.04 (m, 6H), 6.85–6.98 (m, 5H), 6.49–6.52 (s, 2H), 4.55 (s, 2H). 13C NMR (100 MHz, CD3CN): δ 158.7, 151.6, 143.1, 141.7, 136.7, 134.6, 133.0, 131.1, 131.2, 129.8, 129.7, 129.6, 128.8, 128.0, 125.9, 125.8, 124.0, 118.3, 55.0. 31P NMR (162 MHz, CD3CN): δ −9.9 (s), −144.2 (q). MS-ESI+: m/z = 914.1 (M–PF6)+. Anal. Calcd for C51H40BrCuF6N3OP3: C, 57.7; H, 3.8; N, 4.0. Found: C, 57.9; H, 3.5; N, 4.2%.
General procedure for the amination
In a Schlenk tube, a mixture of the catalyst
5-Methyl-2-(1H-pyrazol-1-yl)pyridine (2 ):
1H NMR (400 MHz, CDCl3): δ 8.52 (d, J = 2.4 Hz, 1H), 8.22 (s, 1H), 7.87 (d, J = 8.2 Hz, 1H), 7.72 (s, 1H), 7.62 (d, J = 8.2 Hz, 1H), 6.45 (d, J = 1.6 Hz, 1H), 2.35 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 149.8, 148.0, 141.8, 139.4, 131.0, 126.9, 112.1, 107.6, 18.0. MS-ESI+: m/z = 159.1. Anal. Calcd for C9H9N3: C, 67.9; H, 5.7; N, 26.4. Found: C, 68.2; H, 5.3; N, 26.9%.
5-Methyl-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridine (3 ):
1H NMR (400 MHz, CDCl3): δ 8.26 (s, 1H), 7.70 (d, J = 6.8 Hz, 1H), 7.60 (d, J = 6.8 Hz, 1H), 5.99 (s, 1H), 2.36 (s, 3H), 2.28 (s, 3H), 2.24 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 149.8, 146.1, 139.4, 131.0, 126.9, 112.1, 110.8, 107.6, 29.8, 15.7, 13.8. MS-ESI+: m/z = 187.1. Anal. Calcd for C11H13N3: C, 70.6; H, 7.0; N, 22.4. Found: C, 71.0; H, 6.7; N, 22.6%.
2-Methoxy-6-(1H-pyrazol-1-yl)pyridine (6a ):
1H NMR (400 MHz, CDCl3): δ 8.53 (s, 1H), 7.72 (m, 2H), 7.53 (d, J = 7.6 Hz, 1H), 6.64 (d, J = 8.4 Hz, 1H), 6.46 (d, J = 1.2 Hz, 1H), 3.99 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 163.3, 149.6, 142.0, 141.1, 127.1, 107.8, 107.4, 103.9, 53.6. MS-ESI+: m/z = 175.1. Anal. Calcd for C9H9N3O: C, 61.7; H, 5.2; N, 24.0. Found: C, 61.9; H, 4.9; N, 24.3%.
2-Methoxy-6-(3,5-dimethyl-1H-pyrazol-1-yl)pyridine (6b ):
1H NMR (400 MHz, CDCl3): δ 7.66 (t, J = 8.0 Hz, 1H), 7.42 (d, J = 7.7 Hz, 1H), 6.59 (d, J = 8.0 Hz, 1H), 5.99 (s, 1H), 3.93 (s, 3H), 2.69 (s, 3H), 2.29 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 162.8, 151.6, 149.9, 141.3, 140.7, 109.1, 107.1, 107.0, 53.9, 15.0, 13.8. MS-ESI+: m/z = 203.1. Anal. Calcd for C11H13N3O: C, 65.0; H, 6.5; N, 20.7. Found: C, 65.3; H, 6.1; N, 20.9%.
4-Methoxy-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridine (7b ):
1H NMR (400 MHz, CDCl3): δ 8.19 (d, J = 6.0 Hz, 1H), 7.36 (s, 1H), 6.68 (t, J = 5.6 Hz, 1H), 5.98 (s, 1H), 3.90 (s, 3H), 2.61 (s, 3H), 2.29 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 167.4, 155.4, 149.7, 141.8, 141.1, 109.0, 107.9, 100.3, 55.5, 14.6, 13.7. MS-ESI+: m/z = 203.1. Anal. Calcd for C11H13N3O: C, 65.0; H, 6.5; N, 20.7. Found: C, 65.4; H, 6.2; N, 21.1%.
4-(Trifluoromethyl)-2-(1H-pyrazol-1-yl)pyridine (8a ):
1H NMR (400 MHz, CDCl3): δ 8.64 (s, 1H), 8.20 (d, J = 8.3 Hz, 1H), 7.99 (t, J = 7.7 Hz, 1H), 7.78 (s, 1H), 7.56 (d, J = 7.5 Hz, 1H), 6.51 (d, J = 1.3 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ 151.7, 148.6 (q, J = 36.2 Hz), 142.9, 140.2, 127.7 (q, J = 285.6 Hz), 117.7 (q, J = 2.2 Hz), 115.4 (q, J = 1.0 Hz), 108.6. MS-ESI+: m/z = 213.1. Anal. Calcd for C9H6F3N3: C, 50.7; H, 2.8; N, 19.7. Found: C, 50.9; H, 2.5; N, 19.9%.
4-(Trifluoromethyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridine (8b ):
1H NMR (400 MHz, CDCl3): δ 8.56 (d, J = 4.4 Hz, 1H), 8.20 (s, 1H), 7.33 (d, J = 7.8 Hz, 1H), 6.03 (s, 1H), 2.68 (s, 3H), 2.32 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 155.6, 150.9, 148.6, 142.3, 141.2 (q, J = 33.6 Hz), 129.0, 124.6 (q, J = 276.4 Hz), 115.8 (q, J = 1.2 Hz), 111.5 (q, J = 1.6 Hz), 15.0, 13.7. MS-ESI+: m/z = 241.1. Anal. Calcd for C11H10F3N3: C, 54.8; H, 4.2; N, 17.4. Found: C, 55.1; H, 4.0; N, 17.7%.
6-(Trifluoromethyl)-2-(1H-pyrazol-1-yl)pyridine (9a ):
1H NMR (400 MHz, CDCl3): δ 8.60 (m, 2H), 8.28 (s, 1H), 7.80 (s, 1H), 7.41 (d, J = 4.8 Hz, 1H), 6.52 (s, 1H). 13C NMR (100 MHz, CDCl3): δ 151.5, 146.8 (q, J = 32.2 Hz), 142.8, 140.5, 127.6, 123.0 (q, J = 272.6 Hz), 117.6 (q, J = 2.6 Hz), 115.3 (q, J = 1.4 Hz), 108.4. MS-ESI+: m/z = 213.1. Anal. Calcd for C9H6F3N3: C, 50.7; H, 2.8; N, 19.7. Found: C, 50.9; H, 2.3; N, 20.0%.
6-(Trifluoromethyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridine (9b ):
1H NMR (400 MHz, CDCl3): δ 8.14 (d, J = 8.4 Hz, 1H), 7.93 (t, J = 8.2 Hz, 1H), 7.49 (d, J = 7.6 Hz, 1H), 6.04 (s, 1H), 2.71 (s, 3H), 2.32 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 167.4, 155.4, 153.0, 151.8, 150.5, 149.8, 141.8 (q, J = 30.8 Hz), 122.4 (q, J = 268.2 Hz), 114.0 (q, J = 1.8 Hz), 109.1 (q, J = 1.0 Hz), 100.3, 14.6, 13.7. MS-ESI+: m/z = 241.1. Anal. Calcd for C11H10F3N3: C, 54.8; H, 4.2; N, 17.4. Found: C, 55.0; H, 3.8; N, 17.8%.
5-Chloro-2-(1H-pyrazol-1-yl)pyridine (10a ):
1H NMR (400 MHz, CDCl3): δ 8.53 (s, 1H), 8.37 (s, 1H), 7.96 (d, J = 8.8 Hz, 1H), 7.80–7.75 (m, 2H), 6.49 (d, J = 1.6 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ 149.9, 146.7, 142.5, 138.5, 129.1, 127.2, 113.4, 108.3. MS-ESI+: m/z = 179.0. Anal. Calcd for C8H6ClN3: C, 53.5; H, 3.4; N, 23.4. Found: C, 53.7; H, 3.0; N, 23.9%.
5-Chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridine (10b) :
1H NMR (400 MHz, CDCl3): δ 8.36 (s, 1H), 7.86 (d, J = 8.8 Hz, 1H), 7.75 (d, J = 7.2 Hz, 1H), 6.01 (s, 1H), 2.63 (s, 3H), 2.30 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 152.0, 151.2, 146.1, 141.8, 138.0, 128.4, 116.5, 109.5, 14.7, 13.7. MS-ESI+: m/z = 207.1. Anal. Calcd for C10H10ClN3: C, 57.8; H, 4.9; N, 20.2. Found: C, 57.6; H, 4.6; N, 20.6%.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)pyrazine (12b ):
1H NMR (400 MHz, CDCl3): δ 9.26 (s, 1H), 8.39 (d, J = 3.0 Hz, 2H), 6.06 (s, 1H), 2.66 (s, 3H), 2.33 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 151.2, 149.9, 142.5, 141.2, 140.7, 138.4, 110.0, 14.6, 13.8. MS-ESI+: m/z = 174.1. Anal. Calcd for C9H10N4: C, 62.1; H, 5.8; N, 32.2. Found: C, 62.5; H, 5.5; N, 32.6%.
Crystal structure determination
Crystallographic data for complex
Crystallographic data for complex
Footnotes
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the high-level introduction of talent research start-up foundation of Jiangsu University of Science and Technology.
